Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer
Adoptive transfer of autologous tumor-specific lymphocytes represents a viable treatment method for patients with advanced malignancies. Here, we report a patient’s case with metastatic hormone-refractory New York esophageal squamous cell carcinoma 1 (NY-ESO-1) expressing prostate cancer treated wit...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-01-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/11/1/e005847.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582680534843392 |
|---|---|
| author | Elke Jäger Julia Karbach Claudia Wahle Dragan Kiselicki Kathrin Brand Evgueni Sinelnikov Dirk Gustavus Hans Hoffmeister Hans-Bernd Prisack Akin Atmaca |
| author_facet | Elke Jäger Julia Karbach Claudia Wahle Dragan Kiselicki Kathrin Brand Evgueni Sinelnikov Dirk Gustavus Hans Hoffmeister Hans-Bernd Prisack Akin Atmaca |
| author_sort | Elke Jäger |
| collection | DOAJ |
| description | Adoptive transfer of autologous tumor-specific lymphocytes represents a viable treatment method for patients with advanced malignancies. Here, we report a patient’s case with metastatic hormone-refractory New York esophageal squamous cell carcinoma 1 (NY-ESO-1) expressing prostate cancer treated with in vitro expanded tumor-infiltrating lymphocytes (TILs) in conjunction with IL-2 and immune-checkpoint blockade. Complete and durable tumor remission was observed after three TIL infusions consisting of 1.4×109, 2.0×109, and 8.0×109 T cells, respectively, lasting now for more than 3.5 years. Immunological correlates to the clinical development were the decrease of tumor-driven NY-ESO-1 serum antibody and the drop of prostate-specific antigen to <0.01 µg/L. TILs were reactive against cancer-testis antigen NY-ESO-1, individual tumor mutational proteins (eg, PRPF8, TRPS1), and the androgen receptor splice variant 12. |
| format | Article |
| id | doaj-art-59a10633aff74d6bb16b5bc67cc12c34 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-59a10633aff74d6bb16b5bc67cc12c342025-01-29T11:05:09ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-01-0111110.1136/jitc-2022-005847Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancerElke Jäger0Julia Karbach1Claudia Wahle2Dragan Kiselicki3Kathrin Brand4Evgueni Sinelnikov5Dirk Gustavus6Hans Hoffmeister7Hans-Bernd Prisack8Akin Atmaca91 Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany1 Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany1 Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany1 Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany1 Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany2 Zellwerk GmbH, Oberkrämer, Germany2 Zellwerk GmbH, Oberkrämer, Germany2 Zellwerk GmbH, Oberkrämer, Germany3 NextGen Oncology, Düsseldorf, Germany1Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, GermanyAdoptive transfer of autologous tumor-specific lymphocytes represents a viable treatment method for patients with advanced malignancies. Here, we report a patient’s case with metastatic hormone-refractory New York esophageal squamous cell carcinoma 1 (NY-ESO-1) expressing prostate cancer treated with in vitro expanded tumor-infiltrating lymphocytes (TILs) in conjunction with IL-2 and immune-checkpoint blockade. Complete and durable tumor remission was observed after three TIL infusions consisting of 1.4×109, 2.0×109, and 8.0×109 T cells, respectively, lasting now for more than 3.5 years. Immunological correlates to the clinical development were the decrease of tumor-driven NY-ESO-1 serum antibody and the drop of prostate-specific antigen to <0.01 µg/L. TILs were reactive against cancer-testis antigen NY-ESO-1, individual tumor mutational proteins (eg, PRPF8, TRPS1), and the androgen receptor splice variant 12.https://jitc.bmj.com/content/11/1/e005847.full |
| spellingShingle | Elke Jäger Julia Karbach Claudia Wahle Dragan Kiselicki Kathrin Brand Evgueni Sinelnikov Dirk Gustavus Hans Hoffmeister Hans-Bernd Prisack Akin Atmaca Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer Journal for ImmunoTherapy of Cancer |
| title | Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer |
| title_full | Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer |
| title_fullStr | Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer |
| title_full_unstemmed | Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer |
| title_short | Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer |
| title_sort | tumor infiltrating lymphocytes mediate complete and durable remission in a patient with ny eso 1 expressing prostate cancer |
| url | https://jitc.bmj.com/content/11/1/e005847.full |
| work_keys_str_mv | AT elkejager tumorinfiltratinglymphocytesmediatecompleteanddurableremissioninapatientwithnyeso1expressingprostatecancer AT juliakarbach tumorinfiltratinglymphocytesmediatecompleteanddurableremissioninapatientwithnyeso1expressingprostatecancer AT claudiawahle tumorinfiltratinglymphocytesmediatecompleteanddurableremissioninapatientwithnyeso1expressingprostatecancer AT dragankiselicki tumorinfiltratinglymphocytesmediatecompleteanddurableremissioninapatientwithnyeso1expressingprostatecancer AT kathrinbrand tumorinfiltratinglymphocytesmediatecompleteanddurableremissioninapatientwithnyeso1expressingprostatecancer AT evguenisinelnikov tumorinfiltratinglymphocytesmediatecompleteanddurableremissioninapatientwithnyeso1expressingprostatecancer AT dirkgustavus tumorinfiltratinglymphocytesmediatecompleteanddurableremissioninapatientwithnyeso1expressingprostatecancer AT hanshoffmeister tumorinfiltratinglymphocytesmediatecompleteanddurableremissioninapatientwithnyeso1expressingprostatecancer AT hansberndprisack tumorinfiltratinglymphocytesmediatecompleteanddurableremissioninapatientwithnyeso1expressingprostatecancer AT akinatmaca tumorinfiltratinglymphocytesmediatecompleteanddurableremissioninapatientwithnyeso1expressingprostatecancer |